echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > 100 million-level best-selling cardiovascular drug Chengdu Bitedigoxin Tablets is the first to review

    100 million-level best-selling cardiovascular drug Chengdu Bitedigoxin Tablets is the first to review

    • Last Update: 2022-05-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
      On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
    .
    Up to now, 22 products have been reviewed for heart disease treatment drugs

    .
     
      Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
      Source: NMPA official website
     
      Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
    Atrial fibrillation and other arrhythmias

    .
     
      Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
      Source: Mi intranet database
     
      In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
    74%, of which tablets and injections were the best-selling dosage forms.
    , accounting for 56.
    46% and 42.
    81%, respectively; and in Chinese urban physical
    pharmacy terminals, digoxin tablets accounted for as high as 90%
    .
     
    Chengdu Beite Pharmaceutical Co.
    , Ltd.
    is the first company
      applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
    .
     
      According to data from Minet.
    com,
    up to now, 22 products have been reviewed for
    heart disease
    .
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories

    .
    The above sales are calculated based on the average retail price of the product in the terminal

    .
    Statistics are as of April 20, if there are any omissions, please correct me!
      On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
    .
    Up to now, 22 products have been reviewed for heart disease treatment drugs

    .
     
      Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
      Source: NMPA official website
     
      Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
    Atrial fibrillation and other arrhythmias

    .
     
      Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
      Source: Mi intranet database
     
      In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
    74%, of which tablets and injections were the best-selling dosage forms.
    , accounting for 56.
    46% and 42.
    81%, respectively; and in Chinese urban physical
    pharmacy terminals, digoxin tablets accounted for as high as 90%
    .
     
    Chengdu Beite Pharmaceutical Co.
    , Ltd.
    is the first company
      applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
    .
     
      According to data from Minet.
    com,
    up to now, 22 products have been reviewed for
    heart disease
    .
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories

    .
    The above sales are calculated based on the average retail price of the product in the terminal

    .
    Statistics are as of April 20, if there are any omissions, please correct me!
      On April 19, NMPA's official website released the latest information on approved drugs, and Chengdu Beite Pharmaceutical's digoxin tablets were the first to be reviewed
    .
    Up to now, 22 products have been reviewed for heart disease treatment drugs

    .
     
      Figure 1: Information on the approved products of Chengdu Better Pharmaceuticals
      Source: NMPA official website
     
      Digoxin is a commonly used cardiac glycoside drug, which can slow down the heart rate, effectively improve the symptoms of heart failure and cardiac function, reduce the hospitalization rate and shorten the hospitalization time of patients with severe congestive heart failure.
    Atrial fibrillation and other arrhythmias

    .
     
      Figure 2: The overall sales scale of digoxin (unit: ten thousand yuan)
      Source: Mi intranet database
     
      In the first half of 2021, in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions), the sales growth rate of digoxin reached 56.
    74%, of which tablets and injections were the best-selling dosage forms.
    , accounting for 56.
    46% and 42.
    81%, respectively; and in Chinese urban physical
    pharmacy terminals, digoxin tablets accounted for as high as 90%
    .
    Hospital Hospital Hospital Pharmacy Pharmacy Pharmacy
     
    Chengdu Beite Pharmaceutical Co.
    , Ltd.
    is the first company
      applying for the consistency evaluation of digoxin tablets , and it has been successfully approved; in addition, 4 companies have reported production of digoxin injection according to the new classification, and the relevant acceptance number is under review and approval
    .
    enterprise enterprise enterprise
     
      According to data from Minet.
    com,
    up to now, 22 products have been reviewed for
    heart disease
    .
    heart heart heart
     
      Source: Minet database, the official website of the State Food and Drug Administration, etc.
     
      Note: Minet.
    com China's urban physical pharmacy terminal competition pattern database is an enlarged version of the urban physical pharmacy database that covers 297 cities and above cities nationwide (excluding county and rural physical pharmacies) and continuously monitors all categories

    .
    The above sales are calculated based on the average retail price of the product in the terminal

    .
    Statistics are as of April 20, if there are any omissions, please correct me!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.